Skip to main content
Premium Trial:

Request an Annual Quote

Marijn Dekkers

Thermo Fisher Scientific has agreed to a renegotiated contract with Marijn Dekkers that gives the CEO a base salary of $1.17 million per year as well as a target incentive bonus of 125 percent of base salary, the company disclosed in a filing last week with the US Securities and Exchange Commission. The new contract holds through the end of 2017.
If the company opts to sack Dekkers before the contract ends, it will owe him a buyout of three times his current base salary, three times his target bonus, a pro-rata bonus for the year of the termination, and outplacement services worth up to $50,000.
Dekkers base salary in 2007 was $1.13 million, up from $1.04 million in 2006. He also received a 2007 bonus of $1.9 million.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.